CS
KNSA icon

Credit Suisse’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Credit Suisse’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$571K Hold
28,924
– – ﹤0.01% 2578
2023
Q4 		$507K Buy
28,924
+3,516
+14% +$57.8K ﹤0.01% 2719
2023
Q3 		$441K Sell
25,408
-5,847
-19% -$98.5K ﹤0.01% 2736
2023
Q2 		$440K Buy
31,255
+6,436
+26% +$86.1K ﹤0.01% 2844
2023
Q1 		$267K Buy
24,819
+2,556
+11% +$33.7K ﹤0.01% 3034
2022
Q4 		$334K Sell
22,263
-2,946
-12% -$42.9K ﹤0.01% 2987
2022
Q3 		$324K Buy
25,209
+7,654
+44% +$87.2K ﹤0.01% 3042
2022
Q2 		$170K Sell
17,555
-1,990
-10% -$18.6K ﹤0.01% 3383
2022
Q1 		$194K Buy
19,545
+246
+1% +$2.61K ﹤0.01% 3381
2021
Q4 		$226K Buy
19,299
+3,542
+22% +$43.5K ﹤0.01% 4230
2021
Q3 		$178K Buy
15,757
+752
+5% +$9.79K ﹤0.01% 4251
2021
Q2 		$209K Sell
15,005
-2,418
-14% -$36.7K ﹤0.01% 4267
2021
Q1 		$322K Sell
17,423
-34,736
-67% -$710K ﹤0.01% 3974
2020
Q4 		$921K Buy
52,159
+40,593
+351% +$713K ﹤0.01% 3393
2020
Q3 		$177K Sell
11,566
-15,205
-57% -$285K ﹤0.01% 3859
2020
Q2 		$682K Buy
26,771
+10,052
+60% +$210K ﹤0.01% 3137
2020
Q1 		$259K Sell
16,719
-1,752
-9% -$27.4K ﹤0.01% 3508
2019
Q4 		$204K Buy
18,471
+460
+3% +$4K ﹤0.01% 3977
2019
Q3 		$153K Buy
+18,011
New +$199K ﹤0.01% 3919

Other funds holding KNSA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's KNSA Position: Q1 2024 in Review

Credit Suisse held its Kiniksa Pharmaceuticals (KNSA) position steady in Q1 2024 at 28,924 shares worth $571K. The position accounts for ﹤0.01% of the portfolio, ranked #2578.

Credit Suisse first reported a position in KNSA in Q3 2019 and has held it in 19 quarters since. The position peaked at $921K in Q4 2020. 154 funds tracked by Wall St. Rank hold KNSA as of Q1 2024.

  • Credit Suisse held 28,924 shares of Kiniksa Pharmaceuticals worth $571K as of Q1 2024.
  • Credit Suisse left its Kiniksa Pharmaceuticals share count unchanged in Q1 2024.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2578 holding.
  • Credit Suisse first reported a position in Kiniksa Pharmaceuticals in Q3 2019 and has held it in 19 quarters since.
  • Credit Suisse's Kiniksa Pharmaceuticals position peaked at $921K in Q4 2020.
  • 154 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.